Gareth Sheridan, CEO of Nutriband Inc., has been selected as a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. This prestigious recognition acknowledges Sheridan's significant contributions to transforming Nutriband from an early-stage startup into a publicly listed life sciences company specializing in transdermal drug delivery and abuse-deterrent technologies.
Out of 27 Irish entrepreneurs recognized, Sheridan stands out for his strategic leadership in developing innovative pharmaceutical solutions. The company's lead product, AVERSA™, represents a critical advancement in pain management by preventing the misuse and abuse of opioid patches.
As a finalist, Sheridan will participate in an exclusive CEO retreat in Japan and compete for the overall Entrepreneur of the Year title, which will be announced at a gala event in November. The awards highlight entrepreneurs who demonstrate exceptional innovation, financial performance, and positive societal impact.
Nutriband's focus on developing abuse-deterrent transdermal pharmaceutical products addresses a significant challenge in healthcare, offering potential solutions to minimize drug misuse and accidental exposure. Sheridan's recognition underscores the company's commitment to advancing safe and responsible pharmaceutical technologies.
